<DOC>
	<DOCNO>NCT01146262</DOCNO>
	<brief_summary>Dendritic cell vaccination increasingly use order develop antitumoral immune response . This Phase 2 trial use autologous dendritic cell pulse leukemic apoptotic corpse acute myelogenous leukemia ( AML ) patient first second Complete remission ( CR ) .</brief_summary>
	<brief_title>Vaccination Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells Acute Myelogenous Leukemia ( AML ) Patients First Second Complete Remission ( CR ) ( CD laM )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age â‰¥ 60 year Informed consent sign Serology HIV , hepatitis B , hepatitis C , HTLV 1 2 Syphilis always negative ( new achievement test ) Performance Statute &lt; =2 Must eligible allogeneic transplantation No progressive disease Bone marrow and/or peripheral blast &gt; 50 % chemotherapyBlasts &gt; =2.4 10*8 ( collect prior chemotherapy ) available No contraindication cytapheresis AML CR2 , except M3AML Patients refractory AML induction treatment patient eligible salvage treatment may allow production first complete remission . Patient newly diagnose AML unfavorable cytogenetics ( ) course intensive induction consolidation treatment outpatient possible Patient newly diagnose AML nonadverse cytogenetics AND either refuse participate protocol GOELAMS LAMS2007 , exclusion criterion , indicate participation protocol GOELAMS LAMS2007 ( ) course induction intensive patient treatment consolidation possible Absence donor HLAcompatible family nonfamily absence placental blood available performing allograft . Exclusion Criteria Patients , reason psychological , social geographical boundary , could monitor study No infection visceral ( cardiac , lung , brain , ... ) serious uncontrolled History positive allogeneic bone marrow solid organ transplantation . Previous history autoimmune disease vitiligo History cancer , except cervical carcinoma situ basal cell carcinoma skin unless deem cured 5 year . Inability collect diagnosis relapse AML , enough leukemic cell ( &gt; 2.4 x108 ) Inability collect remission , sufficient number monocyte two leukapheresis maximum Failure obtain maturation monocyte Patient AML 3 Patient may receive allogeneic hematopoietic stem cell No treatment relate treatment molecule preclinical development underway complete MA within last 4 week</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Antitumoral immune response autologous dendritic cell vaccination</keyword>
</DOC>